CAPR U.S. FDA advisers vote against evidence of effectiveness of Capricor's duchenne heart disease therapy deramiocel
CAPR U.S. FDA advisers vote against evidence of effectiveness of Capricor's duchenne heart disease therapy deramiocel
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.